Skip to main content

Table 2 Univariate and multivariate Cox proportional hazards regression models for progression free survival

From: Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC

  Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
D Group, B Group 0.97 (0.64, 1.46) 0.879 1.11 (0.72, 1.72) 0.628
Age (≥ 65, < 65 years) 0.97 (0.64, 1.46) 0.874 1.04 (0.66, 1.66) 0.862
Use of BMA, No use 1.26 (0.84, 1.89) 0.255 1.71 (1.06, 2.77) 0.028
Chemotherapy, No use 1.03 (0.55, 1.93) 0.930 1.19 (0.60, 2.37) 0.618
BMI ≥ 25, < 25 1.85 (1.16, 2.96) 0.010 1.84 (1.11, 3.04) 0.018
PgR+, − 1.02 (0.60, 1.72) 0.952 0.70 (0.38, 1.29) 0.257
Visceral, No visceral 1.98 (1.27, 3.08) 0.002 2.13 (1.31, 3.49) 0.003
Metastatic, De novo 1.05 (0.65, 1.69) 0.855 0.87 (0.49, 1.54) 0.625
Endocrine therapy 2, 0–1 1.34 (0.80, 2.22) 0.265 1.13 (0.60, 2.13) 0.701
Endocrine therapy 3, 0–1 1.22 (0.76, 1.96) 0.409 0.95 (0.56, 1.62) 0.856
Incidence of oral mucositis within 8 weeks, None 1.19 (0.69, 2.04) 0.536 1.41 (0.78, 2.57) 0.260